Data from TGCA sustain that MSI tumors (endometrial, colorectal, stomach, and prostate carcinoma) have recurrent frameshift mutations in JAK1, and these tumors showed reduced expression of interferon response signature [229]. Here, JAK1 is linked to prostate carcinoma.